Get the Stockscreener App
5.30
3.81%
-0.21
After Hours:
5.30
Galecto Inc stock is traded at $5.30, with a volume of 29,074.
It is down -3.81% in the last 24 hours and down -25.14% over the past month.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
See More
Previous Close:
$5.51
Open:
$5.51
24h Volume:
29,074
Relative Volume:
0.74
Market Cap:
$6.98M
Revenue:
-
Net Income/Loss:
$-38.35M
P/E Ratio:
-2.6368
EPS:
-2.01
Net Cash Flow:
$-36.91M
1W Performance:
-5.69%
1M Performance:
-25.14%
6M Performance:
-64.96%
1Y Performance:
-64.38%
1-Day Range:
$5.30
$5.78
1-Week Range:
$5.30
$5.9797
52-Week Range:
$5.30
$23.50
Galecto Inc Stock (GLTO) Company Profile
Name
Galecto Inc
Sector
Industry
Phone
45-70-70-52-10
Address
75 STATE STREET, BOSTON
Compare GLTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLTO
Galecto Inc
|
5.30 | 6.98M | 0 | -38.35M | -36.91M | -1.45 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.13 | 120.56B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
750.22 | 82.44B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
616.55 | 36.87B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
253.07 | 32.64B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.39 | 28.38B | 3.30B | -501.07M | 1.03B | -2.1146 |
Galecto Inc Stock (GLTO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | BofA Securities | Buy |
| Nov-23-20 | Initiated | Credit Suisse | Outperform |
| Nov-23-20 | Initiated | SVB Leerink | Outperform |
Galecto Inc Stock (GLTO) Latest News
Galecto stock hits 52-week low at $5.51 amid market challenges - Investing.com Australia
GLTO (Galecto) Momentum Rank : 2 (As of Nov. 26, 2024) - GuruFocus.com
Idiopathic Pulmonary Fibrosis Market Report 2034, by DelveInsight | Companies: FibroGen, Hoffmann-La Roche Ltd, United Therapeutics, Boehringer Ingelheim, Pliant Therapeutics, Inc., Galecto Biotech - The Globe and Mail
Idiopathic Pulmonary Fibrosis Market Report 2034, - openPR
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
GLTO (Galecto) EBITDA per Share : $-17.96 (TTM As of Sep. 2024) - GuruFocus.com
Galecto (NASDAQ:GLTO) Shares Down 5.3% – Should You Sell? - Defense World
Galecto stock hits 52-week low at $6.46 amid market challenges - Investing.com India
Galecto Inc. (GLTO) Quarterly 10-Q Report - Quartzy
(GLTO) Investment Report - Stock Traders Daily
Galecto, Inc.’s Strategic Shift to Oncology and Liver Diseases: Navigating Risks and Opportunities - MSN
Galecto reports Q3 EPS ($3.39) vs ($7.50) - MSN
Galecto, Inc. Announces Strategic Shift and Financial Overview - MSN
Galecto Reports Third Quarter 2024 Financial Results - The Manila Times
(GLTO) On The My Stocks Page - Stock Traders Daily
Galecto price target raised to $10 from $9 at Oppenheimer - Yahoo Finance
How to Take Advantage of moves in (GLTO) - Stock Traders Daily
Galecto (NASDAQ:GLTO) Price Target Increased to $10.00 by Analysts at Oppenheimer - MarketBeat
Galecto (NASDAQ:GLTO) Given New $10.00 Price Target at Oppenheimer - MarketBeat
Galecto adds Dr. Amy Wechsler to Board of Directors By Investing.com - Investing.com Canada
Galecto stock hits 52-week low at $6.61 amid market challenges - Investing.com Canada
Galecto adds Dr. Amy Wechsler to Board of Directors - Investing.com
Galecto Appoints Dr. Amy Wechsler to Board - TipRanks
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler - The Manila Times
Galecto refocuses on cancer, acquires novel AML drug rights By Investing.com - Investing.com South Africa
Clene Inc (CLNN-Q) QuotePress Release - The Globe and Mail
Galecto stock hits 52-week low at $9.3 amid market challenges - Investing.com
Galecto stock hits 52-week low at $9.3 amid market challenges By Investing.com - Investing.com South Africa
Galecto Expands Oncology Portfolio with Strategic Acquisition - TipRanks
Galecto refocuses on cancer, acquires novel AML drug rights - Investing.com
Galecto Shares Slide on Leukemia Treatment Rights Acquisition - MarketWatch
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines - The Manila Times
Tesla Inc (TSLA-Q) QuotePress Release - The Globe and Mail
TSX Composite Low Volatility (TXLV) QuotePress Release - The Globe and Mail
KBW Bank Index (BKX) QuotePress Release - The Globe and Mail
Charter Communications Inc (CHTR-Q) QuotePress Release - The Globe and Mail
Robusta Coffee 10-T (RMK26) Quote - The Globe and Mail
S&P GSCI Index (GNX) QuotePress Release - The Globe and Mail
TSX North American Pref Stock Index (STNU) QuotePress Release - The Globe and Mail
Nuscale Power Corp (SMR-N) QuotePress Release - The Globe and Mail
King Corn's Royal(s) Connection - The Globe and Mail
Trading (GLTO) With Integrated Risk Controls - Stock Traders Daily
Myelofibrosis Pipeline Forecast 2024: FDA Approvals, Therapies, and Leading Companies by DelveInsight | Galecto Biotech, Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo - The Globe and Mail
Boehringer Gets The First Phase III Hit In IPF For A Decade - Scrip
Short Interest in Galecto, Inc. (NASDAQ:GLTO) Drops By 62.1% - Defense World
Skandinaviska Enskilda Banken AB publ Buys New Stake in GitLab Inc. (NASDAQ:GTLB) - MarketBeat
The Gabelli Convertible and Income Securities Fund (NYSE:GCV) Stock Price Passes Above 50 Day Moving Average of $3.83 - MarketBeat
Amazon.com Inc (AMZN-Q) QuotePress Release - The Globe and Mail
Galecto Inc Stock (GLTO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.61%
1.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):